{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024799","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.737670+00:00","generated_at":"2026-06-21T21:23:54.945583+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProKidney Q3 net loss $33.9M; cash $506.3M; Phase 3 REACT trials on track","bullets":["Cash and equivalents of $506.3M as of Sept 30, 2022, up from $20.6M at Dec 31, 2021, after $596.5M gross proceeds from business combination.","Net loss before noncontrolling interest of $33.9M for Q3 2022 vs $17.1M in Q3 2021; R&D expenses $21.1M vs $14.7M.","Phase 3 proact 1 enrolling up to 600 subjects; first interim data expected Q4 2024; proact 2 enrollment to begin Q1 2023.","Phase 2 REGEN-007 expanded to 50 subjects; interim data expected mid-2023.","Received UK MHRA allowance and positive EMA scientific advice for Phase 3 program supporting eventual MAA."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024799","json":"https://secwatch.observer/filing/0000950170-22-024799.json","markdown":"https://secwatch.observer/filing/0000950170-22-024799.md","text":"https://secwatch.observer/filing/0000950170-22-024799.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000095017022024799/0000950170-22-024799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000095017022024799/prok-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:23:54.945583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a749fef0110a1bffe0e67d2fa9c80735c5e8416b","claim":"PROKIDNEY CORP. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, ProKidney Corp. issued a press release to announce the financial results of ProKidney LP and its subsidiaries for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017022024799/0000950170-22-024799-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}